Owen M Wolkowitz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7494510/publications.pdf

Version: 2024-02-01

208 papers 14,586 citations

18482 62 h-index 22166 113 g-index

219 all docs

219 docs citations

219 times ranked

15228 citing authors

#	Article	IF	CITATIONS
1	An immunogenomic phenotype predicting behavioral treatment response: Toward precision psychiatry for mothers and children with trauma exposure. Brain, Behavior, and Immunity, 2022, 99, 350-362.	4.1	7
2	Epigenetic biotypes of post-traumatic stress disorder in war-zone exposed veteran and active duty males. Molecular Psychiatry, 2021, 26, 4300-4314.	7.9	22
3	A DNA methylation clock associated with age-related illnesses and mortality is accelerated in men with combat PTSD. Molecular Psychiatry, 2021, 26, 4999-5009.	7.9	52
4	Pre-deployment risk factors for PTSD in active-duty personnelÂdeployed to Afghanistan: a machine-learning approach for analyzing multivariate predictors. Molecular Psychiatry, 2021, 26, 5011-5022.	7.9	55
5	HPA axis regulation and epigenetic programming of immune-related genes in chronically stressed and non-stressed mid-life women. Brain, Behavior, and Immunity, 2021, 92, 49-56.	4.1	16
6	Utilization of machine learning for identifying symptom severity military-related PTSD subtypes and their biological correlates. Translational Psychiatry, 2021, 11, 227.	4.8	11
7	"GrimAge,―an epigenetic predictor of mortality, is accelerated in major depressive disorder. Translational Psychiatry, 2021, 11, 193.	4.8	46
8	Serum brain-derived neurotrophic factor remains elevated after long term follow-up of combat veterans with chronic post-traumatic stress disorder. Psychoneuroendocrinology, 2021, 134, 105360.	2.7	6
9	Abnormal levels of mitochondrial proteins in plasma neuronal extracellular vesicles in major depressive disorder. Molecular Psychiatry, 2021, 26, 7355-7362.	7.9	36
10	Pre-treatment allostatic load and metabolic dysregulation predict SSRI response in major depressive disorder: a preliminary report. Psychological Medicine, 2021, 51, 2117-2125.	4.5	16
11	Blood-based mitochondrial respiratory chain function in major depression. Translational Psychiatry, 2021, 11, 593.	4.8	11
12	Multi-omic biomarker identification and validation for diagnosing warzone-related post-traumatic stress disorder. Molecular Psychiatry, 2020, 25, 3337-3349.	7.9	68
13	Association of comorbid depression with inpatient outcomes in critical limb ischemia. Vascular Medicine, 2020, 25, 25-32.	1.5	19
14	Vitamin D and inflammation in major depressive disorder. Journal of Affective Disorders, 2020, 267, 33-41.	4.1	21
15	Epigenetic Biotypes of PTSD in War-Zone Exposed Veteran and Active Duty Males. Biological Psychiatry, 2020, 87, S8-S9.	1.3	2
16	Frailty Index as a clinical measure of biological age in psychiatry. Journal of Affective Disorders, 2020, 268, 183-187.	4.1	20
17	Novel Pharmacological Targets for Combat PTSD—Metabolism, Inflammation, The Gut Microbiome, and Mitochondrial Dysfunction. Military Medicine, 2020, 185, 311-318.	0.8	24
18	Effect of Combat Exposure and Posttraumatic Stress Disorder on Telomere Length and Amygdala Volume. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 678-687.	1.5	10

#	Article	IF	CITATIONS
19	Cortisol, moderated by age, is associated with antidepressant treatment outcome and memory improvement in Major Depressive Disorder: A retrospective analysis. Psychoneuroendocrinology, 2019, 109, 104386.	2.7	11
20	Mechanistic inferences on metabolic dysfunction in posttraumatic stress disorder from an integrated model and multiomic analysis: role of glucocorticoid receptor sensitivity. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E879-E898.	3.5	22
21	Metabolomic analysis of male combat veterans with post traumatic stress disorder. PLoS ONE, 2019, 14, e0213839.	2.5	54
22	Accelerating research on biological aging and mental health: Current challenges and future directions. Psychoneuroendocrinology, 2019, 106, 293-311.	2.7	61
23	Plasma serotonin levels are associated with antidepressant response to SSRIs. Journal of Affective Disorders, 2019, 250, 65-70.	4.1	50
24	Is Depression Associated With Accelerated Aging? Mechanisms and Implications. , 2019, , 207-229.		2
25	228. Cross-Sectional and Longitudinal Studies of Cellular Aging and Related Biomarkers in Combat PTSD. Biological Psychiatry, 2019, 85, S94-S95.	1.3	0
26	Improvement in indices of cellular protection after psychological treatment for social anxiety disorder. Translational Psychiatry, 2019, 9, 340.	4.8	15
27	Accelerated aging in serious mental disorders. Current Opinion in Psychiatry, 2019, 32, 381-387.	6.3	30
28	Low serum brain-derived neurotrophic factor is associated with suicidal ideation in major depressive disorder. Psychiatry Research, 2019, 273, 108-113.	3.3	29
29	Metabolism, Metabolomics, and Inflammation in Posttraumatic Stress Disorder. Biological Psychiatry, 2018, 83, 866-875.	1.3	131
30	High levels of mitochondrial DNA are associated with adolescent brain structural hypoconnectivity and increased anxiety but not depression. Journal of Affective Disorders, 2018, 232, 283-290.	4.1	17
31	F174. Higher Baseline Plasma Serotonin, and a Greater Decrease in Serotonin Over Treatment, is Associated With Better SSRI Response in MDD. Biological Psychiatry, 2018, 83, S306.	1.3	1
32	62. Circulating Cell-Free Mitochondrial DNA – a Novel Marker of Mitochondrial Stress Associated With Suicidality and Major Depressive Disorder. Biological Psychiatry, 2018, 83, S25-S26.	1.3	1
33	The association of comorbid depression with mortality and amputation in veterans with peripheral artery disease. Journal of Vascular Surgery, 2018, 68, 536-545.e2.	1.1	43
34	S13. Can Psychological Treatment Slow Down Cellular Aging in Social Anxiety Disorder? An Intervention Study Evaluating Changes in Telomere Length and Telomerase Activity. Biological Psychiatry, 2018, 83, S351-S352.	1.3	0
35	Circulating cell-free mitochondrial DNA, but not leukocyte mitochondrial DNA copy number, is elevated in major depressive disorder. Neuropsychopharmacology, 2018, 43, 1557-1564.	5.4	135
36	Depression, telomeres and mitochondrial DNA: between- and within-person associations from a 10-year longitudinal study. Molecular Psychiatry, 2018, 23, 850-857.	7.9	68

#	Article	IF	Citations
37	Posttraumatic stress disorder, symptoms, and white matter abnormalities among combat-exposed veterans. Brain Imaging and Behavior, 2018, 12, 989-999.	2.1	18
38	Epigenetic Age in Male Combat-Exposed War Veterans: Associations with Posttraumatic Stress Disorder Status. Molecular Neuropsychiatry, 2018, 4, 90-99.	2.9	35
39	233. Indices of Cellular Health are Associated With Antidepressant Treatment Response. Biological Psychiatry, 2018, 83, S93-S94.	1.3	0
40	Accelerated biological aging in serious mental disorders. World Psychiatry, 2018, 17, 144-145.	10.4	19
41	Depression severity is associated with increased inflammation in veterans with peripheral artery disease. Vascular Medicine, 2018, 23, 445-453.	1.5	14
42	Severity of anxiety– but not depression– is associated with oxidative stress in Major Depressive Disorder. Journal of Affective Disorders, 2017, 219, 193-200.	4.1	42
43	1005. Pre-Treatment Allostatic Load and Metabolic Dysregulation Predict Antidepressant Response in Major Depressive Disorder. Biological Psychiatry, 2017, 81, S406-S407.	1.3	0
44	Biological predictors of insulin resistance associated with posttraumatic stress disorder in young military veterans. Psychoneuroendocrinology, 2017, 82, 91-97.	2.7	44
45	709. Increased Circulating Blood Cell Counts in Combat-Related PTSD: Associations with Inflammation and Symptom Severity. Biological Psychiatry, 2017, 81, S287-S288.	1.3	0
46	Oxidative stress, inflammation and treatment response in major depression. Psychoneuroendocrinology, 2017, 76, 197-205.	2.7	332
47	Higher serum DHEA concentrations before and after SSRI treatment are associated with remission of major depression. Psychoneuroendocrinology, 2017, 77, 122-130.	2.7	20
48	Increased circulating blood cell counts in combat-related PTSD: Associations with inflammation and PTSD severity. Psychiatry Research, 2017, 258, 330-336.	3.3	41
49	Whole-genome DNA methylation status associated with clinical PTSD measures of OIF/OEF veterans. Translational Psychiatry, 2017, 7, e1169-e1169.	4.8	45
50	510. Major Depression, Childhood Trauma, Parenting Styles and Oxidative Stress: A Well-controlled Study in Unmedicated Individuals. Biological Psychiatry, 2017, 81, S207-S208.	1.3	2
51	Telomere length is inversely correlated with urinary stress hormone levels in healthy controls but not in un-medicated depressed individuals-preliminary findings. Journal of Psychosomatic Research, 2017, 99, 177-180.	2.6	8
52	Leukocyte telomere length: Effects of schizophrenia, age, and gender. Journal of Psychiatric Research, 2017, 85, 42-48.	3.1	35
53	Increased pro-inflammatory milieu in combat related PTSD – A new cohort replication study. Brain, Behavior, and Immunity, 2017, 59, 260-264.	4.1	93
54	Alterations in leukocyte transcriptional control pathway activity associated with major depressive disorder and antidepressant treatment. Translational Psychiatry, 2016, 6, e821-e821.	4.8	33

#	Article	IF	Citations
55	A population of atypical CD56â^'CD16+ natural killer cells is expanded in PTSD and is associated with symptom severity. Brain, Behavior, and Immunity, 2016, 56, 264-270.	4.1	25
56	Neuroscience-informed auditory training in schizophrenia: A final report of the effects on cognition and serum brain-derived neurotrophic factor. Schizophrenia Research: Cognition, 2016, 3, 1-7.	1.3	47
57	Cortisol/DHEA ratio and hippocampal volume: A pilot study in major depression and healthy controls. Psychoneuroendocrinology, 2016, 72, 139-146.	2.7	29
58	Elevated plasma F2-isoprostane levels in schizophrenia. Schizophrenia Research, 2016, 176, 320-326.	2.0	31
59	Leukocyte Telomere Length Predicts SSRI Response in Major Depressive Disorder: A Preliminary Report. Molecular Neuropsychiatry, 2016, 2, 88-96.	2.9	32
60	Unresolved Issues in Longitudinal Telomere Length Research: Response to Susser et al American Journal of Psychiatry, 2016, 173, 1147-1149.	7.2	5
61	The Association Between Psychiatric Disorders and Telomere Length: A Meta-Analysis Involving 14,827 Persons. Psychosomatic Medicine, 2016, 78, 776-787.	2.0	179
62	Depressive and Anxiety Disorders Showing Robust, but Non-Dynamic, 6-Year Longitudinal Association With Short Leukocyte Telomere Length. American Journal of Psychiatry, 2016, 173, 617-624.	7.2	54
63	Global arginine bioavailability, a marker of nitric oxide synthetic capacity, is decreased in PTSD and correlated with symptom severity and markers of inflammation. Brain, Behavior, and Immunity, 2016, 52, 153-160.	4.1	65
64	Association of dimensional psychological health measures with telomere length in male war veterans. Journal of Affective Disorders, 2016, 190, 537-542.	4.1	38
65	Mitochondrial DNA copy number is reduced in male combat veterans with PTSD. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 10-17.	4.8	73
66	Telomere length is inversely correlated with urinary stress hormone levels in healthy controls but not in un-medicated depressed individuals – Preliminary findings. Psychoneuroendocrinology, 2015, 61, 61.	2.7	0
67	Psychiatric disorders and leukocyte telomere length: Underlying mechanisms linking mental illness with cellular aging. Neuroscience and Biobehavioral Reviews, 2015, 55, 333-364.	6.1	264
68	Evidence for disrupted gray matter structural connectivity in posttraumatic stress disorder. Psychiatry Research - Neuroimaging, 2015, 234, 194-201.	1.8	47
69	PBMC telomerase activity, but not leukocyte telomere length, correlates with hippocampal volume in major depression. Psychiatry Research - Neuroimaging, 2015, 232, 58-64.	1.8	33
70	Anxiety disorders and accelerated cellular ageing. British Journal of Psychiatry, 2015, 206, 371-378.	2.8	54
71	Is Post-Traumatic Stress Disorder Associated with Premature Senescence? A Review of the Literature. American Journal of Geriatric Psychiatry, 2015, 23, 709-725.	1.2	185
72	Telomerase activation as a possible mechanism of action for psychopharmacological interventions. Drug Discovery Today, 2015, 20, 1305-1309.	6.4	48

#	Article	IF	Citations
73	Peripheral telomere length and hippocampal volume in adolescents with major depressive disorder. Translational Psychiatry, 2015, 5, e676-e676.	4.8	43
74	Telomere length and cortisol reactivity in children of depressed mothers. Molecular Psychiatry, 2015, 20, 615-620.	7.9	154
75	A Preliminary Study: Efficacy of Mindfulness-Based Cognitive Therapy versus Sertraline as First-line Treatments for Major Depressive Disorder. Mindfulness, 2015, 6, 475-482.	2.8	23
76	Peripheral antioxidant markers are associated with total hippocampal and CA3/dentate gyrus volume in MDD and healthy controls–preliminary findings. Psychiatry Research - Neuroimaging, 2014, 224, 168-174.	1.8	31
77	Adverse Consequences of Glucocorticoid Medication: Psychological, Cognitive, and Behavioral Effects. American Journal of Psychiatry, 2014, 171, 1045-1051.	7.2	168
78	Dysregulated physiological stress systems and accelerated cellular aging. Neurobiology of Aging, 2014, 35, 1422-1430.	3.1	89
79	Major depressive disorder and accelerated cellular aging: results from a large psychiatric cohort study. Molecular Psychiatry, 2014, 19, 895-901.	7.9	227
80	Cellular aging in depression: Permanent imprint or reversible process?. BioEssays, 2014, 36, 968-978.	2.5	41
81	Proinflammatory milieu in combat-related PTSD is independent of depression and early life stress. Brain, Behavior, and Immunity, 2014, 42, 81-88.	4.1	178
82	Adverse childhood experiences and leukocyte telomere maintenance in depressed and healthy adults. Journal of Affective Disorders, 2014, 169, 86-90.	4.1	51
83	Good stress, bad stress and oxidative stress: Insights from anticipatory cortisol reactivity. Psychoneuroendocrinology, 2013, 38, 1698-1708.	2.7	336
84	Dysregulated relationship of inflammation and oxidative stress in major depression. Brain, Behavior, and Immunity, 2013, 31, 143-152.	4.1	199
85	Resting-State Functional Connectivity of Subgenual Anterior Cingulate Cortex in Depressed Adolescents. Biological Psychiatry, 2013, 74, 898-907.	1.3	300
86	Spontaneous brain activity in combat related PTSD. Neuroscience Letters, 2013, 547, 1-5.	2.1	76
87	Dysregulated diurnal cortisol pattern is associated with glucocorticoid resistance in women with major depressive disorder. Biological Psychology, 2013, 93, 150-158.	2.2	109
88	Stress and telomere biology: A lifespan perspective. Psychoneuroendocrinology, 2013, 38, 1835-1842.	2.7	340
89	Altered Cerebral Perfusion in Executive, Affective, and Motor Networks During Adolescent Depression. Journal of the American Academy of Child and Adolescent Psychiatry, 2013, 52, 1076-1091.e2.	0.5	72
90	BDNF Serum Concentrations Show No Relationship with Diagnostic Group or Medication Status in Neurodegenerative Disease. Current Alzheimer Research, 2012, 9, 815-821.	1.4	17

#	Article	IF	Citations
91	Maintenance of a positive outlook during acute stress protects against pro-inflammatory reactivity and future depressive symptoms. Brain, Behavior, and Immunity, 2012, 26, 346-352.	4.1	94
92	Stress appraisals and cellular aging: A key role for anticipatory threat in the relationship between psychological stress and telomere length. Brain, Behavior, and Immunity, 2012, 26, 573-579.	4.1	131
93	Resting leukocyte telomerase activity is elevated in major depression and predicts treatment response. Molecular Psychiatry, 2012, 17, 164-172.	7.9	112
94	Does cellular aging relate to patterns of allostasis?. Physiology and Behavior, 2012, 106, 40-45.	2.1	181
95	Cell aging and resilience: associations between daily emotion regulation and increased telomerase activity. HÃ \P gre Utbildning, 2012, 3, .	3.0	1
96	Cortisol awakening response and cortisol/DHEA ratio associations with hippocampal volume in MDD. HÃ \P gre Utbildning, 2012, 3, .	3.0	2
97	Higher fasting glucose levels are associated with reduced circulating angiogenic cell migratory capacity among healthy individuals. American Journal of Cardiovascular Disease, 2012, 2, 12-9.	0.5	4
98	Divergent Trajectories of Physical, Cognitive, and Psychosocial Aging in Schizophrenia. Schizophrenia Bulletin, 2011, 37, 451-455.	4.3	141
99	Serum BDNF levels before treatment predict SSRI response in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1623-1630.	4.8	133
100	Leukocyte Telomere Length in Major Depression: Correlations with Chronicity, Inflammation and Oxidative Stress - Preliminary Findings. PLoS ONE, 2011, 6, e17837.	2.5	353
101	Physical Activity Moderates Effects of Stressor-Induced Rumination on Cortisol Reactivity. Psychosomatic Medicine, 2011, 73, 604-611.	2.0	81
102	Intensive meditation training, immune cell telomerase activity, and psychological mediators. Psychoneuroendocrinology, 2011, 36, 664-681.	2.7	361
103	Greater endogenous estrogen exposure is associated with longer telomeres in postmenopausal women at risk for cognitive decline. Brain Research, 2011, 1379, 224-231.	2.2	74
104	Childhood Trauma Associated with Short Leukocyte Telomere Length in Posttraumatic Stress Disorder. Biological Psychiatry, 2011, 70, 465-471.	1.3	223
105	Of sound mind and body: depression, disease, and accelerated aging. Dialogues in Clinical Neuroscience, 2011, 13, 25-39.	3.7	175
106	Analyses and comparisons of telomerase activity and telomere length in human T and B cells: Insights for epidemiology of telomere maintenance. Journal of Immunological Methods, 2010, 352, 71-80.	1.4	369
107	Depression gets old fast: do stress and depression accelerate cell aging?. Depression and Anxiety, 2010, 27, 327-338.	4.1	242
108	Dynamics of telomerase activity in response to acute psychological stress. Brain, Behavior, and Immunity, 2010, 24, 531-539.	4.1	192

#	Article	IF	Citations
109	Serum brain-derived neurotrophic factor predicts responses to escitalopram in chronic posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1279-1284.	4.8	45
110	Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. Journal of Psychiatric Research, 2009, 43, 962-969.	3.1	171
111	Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Frontiers in Neuroendocrinology, 2009, 30, 65-91.	5.2	600
112	Glucocorticoids. Annals of the New York Academy of Sciences, 2009, 1179, 19-40.	3.8	149
113	Pessimism correlates with leukocyte telomere shortness and elevated interleukin-6 in post-menopausal women. Brain, Behavior, and Immunity, 2009, 23, 446-449.	4.1	135
114	Is Serum Brain-Derived Neurotrophic Factor a Biomarker for Cognitive Enhancement in Schizophrenia?. Biological Psychiatry, 2009, 66, 549-553.	1.3	215
115	EDITORIAL. World Journal of Biological Psychiatry, 2008, 9, 2-5.	2.6	26
116	The "Steroid Dementia Syndrome― A Possible Model of Human Glucocorticoid Neurotoxicity. Neurocase, 2007, 13, 189-200.	0.6	43
117	Cell aging in relation to stress arousal and cardiovascular disease risk factors. Psychoneuroendocrinology, 2006, 31, 277-287.	2.7	391
118	Catecholamine Response to Methamphetamine is Related to Glucocorticoid Levels but not to Pleasurable Subjective Response. Pharmacopsychiatry, 2006, 39, 100-108.	3.3	1
119	Repeated psychological stress testing in stimulant-dependent patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 669-677.	4.8	30
120	Hormonal changes with cholesterol reduction: a double-blind pilot study. Journal of Clinical Pharmacy and Therapeutics, 2004, 29, 71-73.	1.5	9
121	Chronic pregnenolone effects in normal humans: attenuation of benzodiazepine-induced sedation. Psychoneuroendocrinology, 2004, 29, 486-500.	2.7	33
122	The "Steroid Dementia Syndrome― An Unrecognized Complication of Glucocorticoid Treatment. Annals of the New York Academy of Sciences, 2004, 1032, 191-194.	3.8	84
123	Neurotransmitters, neurosteroids and neurotrophins: New models of the pathophysiology and treatment of depression. World Journal of Biological Psychiatry, 2003, 4, 98-102.	2.6	22
124	Behavioral Implications of Lowering Cholesterol Levels: A Double-Blind Pilot Study. Psychosomatics, 2003, 44, 412-414.	2.5	35
125	Altering Cortisol Level does not Change the Pleasurable Effects of Methamphetamine in Humans. Neuropsychopharmacology, 2003, 28, 1677-1684.	5.4	31
126	Benzodiazepines in Schizophrenia: Prefrontal Cortex Atrophy Predicts Clinical Response to Alprazolam Augmentation. World Journal of Biological Psychiatry, 2002, 3, 221-224.	2.6	7

#	Article	IF	CITATIONS
127	Dehydroepiandrosterone Supplementation and Bone Turnover in Middle-Aged to Elderly Men. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1544-1549.	3.6	39
128	Double-Blind Antiglucocorticoid Treatment in Schizophrenia and Schizoaffective Disorder: A Pilot Study. World Journal of Biological Psychiatry, 2002, 3, 156-161.	2.6	13
129	Cortisol levels predict cognitive impairment induced by electroconvulsive therapy. Biological Psychiatry, 2001, 50, 331-336.	1.3	44
130	Movement Disorder, Memory, Psychiatric Symptoms and Serum DHEA Levels in Schizophrenic and Schizoaffective Patients. World Journal of Biological Psychiatry, 2001, 2, 99-102.	2.6	61
131	Psychoneuroendocrine aspects of treatment-resistant mood disorders. , 2001, , 49-79.		0
132	Antiglucocorticoid drugs in the treatment of depression. Expert Opinion on Investigational Drugs, 2001, 10, 1789-1796.	4.1	74
133	Stress Hormone-Related Psychopathology: Pathophysiological and Treatment Implications. World Journal of Biological Psychiatry, 2001, 2, 115-143.	2.6	116
134	Dehydroepiandrosterone in aging and mental health., 2000,, 144-167.		1
135	The Role of Dehydroepiandrosterone (DHEA) in Psychiatry. Psychiatric Annals, 2000, 30, 123-128.	0.1	7
136	Severity of depression in abstinent alcoholics is associated with monoamine metabolites and dehydroepiandrosterone-sulfate concentrations. Psychiatry Research, 1999, 89, 97-106.	3.3	54
137	Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biological Psychiatry, 1999, 45, 1070-1074.	1.3	160
138	Estrogen replacement therapy and cognitive decline in memory-impaired post-menopausal women. Biological Psychiatry, 1999, 46, 182-188.	1.3	67
139	Treatment of Depression With Antiglucocorticoid Drugs. Psychosomatic Medicine, 1999, 61, 698-711.	2.0	153
140	Double-Blind Treatment of Major Depression With Dehydroepiandrosterone. American Journal of Psychiatry, 1999, 156, 646-649.	7.2	357
141	Dr. Knutson and Colleagues Reply. American Journal of Psychiatry, 1999, 156, 985a-985.	7.2	0
142	Partial reversal of stress-induced behavioral sensitization to amphetamine following metyrapone treatment. Brain Research, 1998, 783, 133-142.	2,2	27
143	Selective Alteration of Personality and Social Behavior by Serotonergic Intervention. American Journal of Psychiatry, 1998, 155, 373-379.	7.2	536
144	Dehydroepiandrosterone (DHEA) treatment of depression. Biological Psychiatry, 1997, 41, 311-318.	1.3	308

#	Article	IF	Citations
145	Glucocorticoid Medication, Memory and Steroid Psychosis in Medical Illness. Annals of the New York Academy of Sciences, 1997, 823, 81-96.	3.8	129
146	Serotonergic Intervention Increases Affiliative Behavior in Humans. Annals of the New York Academy of Sciences, 1997, 807, 492-493.	3.8	30
147	NOVEL STRATEGIES FOR TREATMENT-RESISTANT DEPRESSION. Psychiatric Clinics of North America, 1996, 19, 387-405.	1.3	7
148	Human Pharmacokinetics and Tolerability of Lâ€365,260, a Novel Cholecystokininâ€B Antagonist. Journal of Clinical Pharmacology, 1996, 36, 292-300.	2.0	7
149	The Effects of Clozapine on Symptom Reduction, Neurocognitive Function, and Clinical Management in Treatment-Refractory State Hospital Schizophrenic Inpatients. Neuropsychopharmacology, 1996, 15, 361-369.	5.4	116
150	Memory facilitation following the administration of the benzodiazepine triazolam Experimental and Clinical Psychopharmacology, 1995, 3, 298-303.	1.8	14
151	Antidepressant and Cognitionâ€Enhancing Effects of DHEA in Major Depression. Annals of the New York Academy of Sciences, 1995, 774, 337-339.	3.8	80
152	Prospective controlled studies of the behavioral and biological effects of exogenous corticosteroidsâ-†. Psychoneuroendocrinology, 1994, 19, 233-255.	2.7	181
153	Antiglucocorticoid medication effects on specific depressive symptoms. Biological Psychiatry, 1994, 35, 678-679.	1.3	3
154	Steroid modulation of human memory: Biochemical correlates. Biological Psychiatry, 1993, 33, 744-746.	1.3	34
155	Ketoconazole administration in hypercortisolemic depression. American Journal of Psychiatry, 1993, 150, 810-812.	7.2	124
156	Beneficial Effects of Nalmefene Augmentation in Neuroleptic-Stabilized Schizophrenic Patients. Neuropsychopharmacology, 1993, 9, 111-115.	5.4	30
157	Rational Polypharmacy in Schizophrenia. Annals of Clinical Psychiatry, 1993, 5, 79-80.	0.6	26
158	Quantitative Electroencephalographic Correlates of Steroid Administration in Man. Neuropsychobiology, 1993, 27, 224-230.	1.9	9
159	The Pathophysiologic Significance of Hyperadrenocorticism: Antiglucocorticoid Strategies. Psychiatric Annals, 1993, 23, 682-690.	0.1	23
160	Behavioral Side Effects of Corticosteroid Therapy. Psychiatric Annals, 1993, 23, 703-708.	0.1	13
161	Dr. Wolkowitz and Dr. Pickar Reply. American Journal of Psychiatry, 1992, 149, 422-422.	7.2	6
162	Plasma levels of catecholamines and corticotrophin during acute glucopenia induced by 2-deoxy-D-glucose in normal man. Clinical Autonomic Research, 1992, 2, 359-366.	2.5	24

#	Article	IF	Citations
163	Selective effects of triazolam on memory. Psychopharmacology, 1992, 106, 341-345.	3.1	72
164	Benzodiazepine responsivity in schizophrenia. Schizophrenia Research, 1991, 4, 296.	2.0	1
165	MRI Deep white matter hyperintensity in a psychiatric population. Biological Psychiatry, 1991, 29, 918-922.	1.3	29
166	Models for Research in Consultation Psychiatry. Advances in Psychosomatic Medicine, 1990, 20, 125-135.	2.2	0
167	Neurochemical and Neural Mechanisms of Positive and Negative Symptoms in Schizophrenia. Modern Problems of Pharmacopsychiatry, 1990, 24, 124-151.	2.5	16
168	Prednisone Effects on Neurochemistry and Behavior. Archives of General Psychiatry, 1990, 47, 963.	12.3	122
169	Suicidality and corticosteroid psychosis. Biological Psychiatry, 1990, 27, 459.	1.3	5
170	Drug trials and heterogeneity in schizophrenia: The mean is not the end. Biological Psychiatry, 1990, 28, 1021-1025.	1.3	13
171	Hunger in humans induced by MK-329, a specific peripheral-type cholecystokinin receptor antagonist. Biological Psychiatry, 1990, 28, 169-173.	1.3	62
172	Prednisone effects on blood-brain barrier permeability and CNS IgG synthesis in healthy humans. Psychoneuroendocrinology, 1990, 15, 155-158.	2.7	8
173	Specificity of plasma HVA response to dexamethasone in psychotic depression. Psychiatry Research, 1989, 29, 177-186.	3.3	17
174	Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: Correlations with CSF HVA. Biological Psychiatry, 1989, 25, 431-439.	1.3	25
175	TRH test in schizophrenic patients and controls. Biological Psychiatry, 1989, 25, 523-526.	1.3	6
176	High prevalence of visual hallucinations in research subjects with chronic schizophrenia. American Journal of Psychiatry, 1989, 146, 526-528.	7.2	131
177	Long-lasting behavioral changes following prednisone withdrawal. JAMA - Journal of the American Medical Association, 1989, 261, 1731-1732.	7.4	21
178	Alprazolam augmentation of neuroleptics in schizophrenia. American Journal of Psychiatry, 1989, 146, 1087-8.	7.2	1
179	Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers. Psychiatry Research, 1988, 25, 187-194.	3.3	65
180	Neurobiological correlates of stress in schizophrenia. Schizophrenia Research, 1988, 1, 250-251.	2.0	0

#	Article	IF	CITATIONS
181	Single-dose naloxone acutely reduces eating in obese humans: Behavioral and biochemical effects. Biological Psychiatry, 1988, 24, 483-487.	1.3	28
182	RBC folic acid levels and cognitive performance in elderly patients: A preliminary report. Biological Psychiatry, 1988, 24, 352-354.	1.3	38
183	Alprazolam Augmentation of the Antipsychotic Effects of Fluphenazine in Schizophrenic Patients. Archives of General Psychiatry, 1988, 45, 664.	12.3	84
184	Dexamethasone effects on dopamine and the "prolactin suppression test― Acta Psychiatrica Scandinavica, 1988, 77, 618-619.	4.5	2
185	Alternate-Day Corticosteroid Treatment, Mood and Plasma HVA in Patients with Systemic Lupus erythematosus. Neuropsychobiology, 1988, 19, 17-19.	1.9	3
186	Metabolic stress effects in normal volunteers and schizophrenic patients. Psychopharmacology Bulletin, 1988, 24, 431-3.	0.0	9
187	Prednisone-induced behavioral and biological changes in medically healthy volunteers. Psychopharmacology Bulletin, 1988, 24, 492-4.	0.0	9
188	The Effects of Dexamethasone on Plasma Homovanillic Acid and 3-Methoxy-4-hydroxyphenylglycol. Archives of General Psychiatry, 1987, 44, 782.	12.3	30
189	Dr. Amsterdam and Associates Reply. American Journal of Psychiatry, 1987, 144, 1375-1375.	7.2	6
190	Prednisone decreases CSF somatostatin in healthy humans: Implications for neuropsychiatric illness. Life Sciences, 1987, 41, 1929-1933.	4.3	27
191	Chronic corticosterone administration in rats: Behavioral and biochemical evidence of increased central dopaminergic activity. European Journal of Pharmacology, 1986, 122, 329-338.	3.5	69
192	Pre- and post-dexamethasone plasma ACTH levels in depressed patients and normal controls. Journal of Affective Disorders, 1986, 10, 95-99.	4.1	34
193	Endogenous opioid regulation of hypothalamo-pituitary-adrenal axis activity in schizophrenia. Biological Psychiatry, 1986, 21, 366-373.	1.3	15
194	Neurobiologic Correlates. Annals of the New York Academy of Sciences, 1986, 487, 189-196.	3.8	33
195	Dr. Wolkowitz and Associates Reply. American Journal of Psychiatry, 1986, 143, 1312-1313.	7.2	10
196	Methylphenidate-Induced Cardiac Arrhythmias. New England Journal of Medicine, 1986, 315, 1485-1485.	27.0	27
197	A Psychopharmacological Perspective of Cognitive Functions. Neuropsychobiology, 1985, 14, 88-96.	1.9	18
198	Naloxone's effect on cognitive functioning in drug-free and diazepam-treated normal humans. Psychopharmacology, 1985, 85, 221-223.	3.1	17

#	Article	IF	CITATIONS
199	A Psychopharmacological Perspective of Cognitive Functions. Neuropsychobiology, 1985, 14, 133-156.	1.9	35
200	Self-Destructive Dermatoses. Psychiatric Clinics of North America, 1985, 8, 291-298.	1.3	25
201	Effect of Naloxone on Food Consumption in Obesity. New England Journal of Medicine, 1985, 313, 327-327.	27.0	18
202	Dexamethasone increases plasma HVA but not MHPG in normal humans. Psychiatry Research, 1985, 16, 101-109.	3.3	43
203	Pathologic Gambling and Other Risk-Taking Pursuits. Psychiatric Clinics of North America, 1985, 8, 311-322.	1.3	19
204	Neural and Molecular Mechanisms in Anxiety. Psychiatric Clinics of North America, 1985, 8, 145-158.	1.3	9
205	Evidence for a daily rhythm of plasma HVA in normal controls but not in schizophrenic patients. Psychopharmacology Bulletin, 1985, 21, 694-7.	0.0	27
206	Development of differences in response latencies to right and left visual fields. Brain and Cognition, 1984, 3, 335-342.	1.8	5
207	Marijuana: Differential effects on right and left hemisphere functions in man. Life Sciences, 1977, 21, 1793-1799.	4. 3	15
208	Neuropsychiatric Effects of Dehydroepiandrosterone (DHEA). , 0, , .		4